All In Biotech

Drug Trial Radar · NCT03387098

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Last checked: Nov 20, 2026Latest source record: May 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

4

Actual

Start

Dec 28, 2017

Primary completion

Sep 12, 2018

Study completion Jan 15, 2019

Sponsor

Lead sponsor
ImmunityBio, Inc.Industry
Sponsor type
Industry
First posted
Dec 29, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy.

Conditions

  • Pancreatic Cancer

Interventions

  • Aldoxorubicin HClDrug

    Aldoxorubicin hydrochloride

  • ALT-803Biological

    Recombinant human super agonist interleukin-15 (IL-15) complex

  • ETBX-011Biological

    Ad5 \[E1-, E2b-\]-CEA

  • GI-4000Biological

    Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins

  • haNK for infusionBiological

    NK-92 \[CD16.158V, ER IL-2\]

  • avelumabBiological

    Recombinant human anti-PD-L1 IgG1 monoclonal antibody

  • bevacizumabBiological

    Recombinant human anti-VEGF IgG1 monoclonal

  • CapecitabineDrug

    5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

  • CyclophosphamideDrug

    2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

  • FluorouracilDrug

    5-fluoro-2,4 (1H,3H)-pyrimidinedione

  • LeucovorinDrug

    L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

  • nab-PaclitaxelDrug

    Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

  • lovazaDrug

    Omega-3-acid ethyl esters

  • OxaliplatinDrug

    cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum

  • SBRTProcedure

    Stereotactic Body Radiation Therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs), Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.Time frame: 30 days after last dose, up to 8 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chan Soon-Shiong Institute for Medicine

    El Segundo, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.